Based on these data, we suggest that the combination of alpelisib and eribulin suppresses PIK3CA-mutated, paclitaxel-resistant endometrial cancer cells more effectively by inhibiting both the PI3K/AKT and EMT pathways. Here, PIK3CA is linked to endometrial cancer.